Antibiotic resistance is widely held to be the biggest challenge to modern medicine. If antibiotic resistance becomes the norm, routine surgery will no longer be routine, cancer chemotherapy will put patients at risk of death from infection and immune suppression for organ transplants will no longer be safe. If nothing is done, tens of millions of extra deaths are expected annually by 2050 at a cost of 100s of trillions to the global economy.
By accessing what we call the dark proteome – the >90% of proteins that have not been accessible to genetic or chemical screening strategies – metaLinear expects to break through the bottleneck that has meant no new drug targets, and no new chemical classes of antibiotics, despite > 40 years of effort by big and small pharma alike.
metaLinear will create lucrative revenue opportunities through IP in novel targets, IP in new drug candidates, and partnerships with large pharma. Talk to us about investment opportunities, partnerships and career openings.